Senesco Expands On Recently Announced Preclinical Pancreatic Islet Data
Apr 17th 2008Drug InformationGastroIntestinal / Gastroentorology
Senesco Technologies, Inc. (”Senesco” or the “Company”) (Amex: SNT) announced further details of Dr. Raghavendra Mirmira’s preclinical pancreatic islet cell research that was funded by the Company. Using a small interfering RNA (siRNA) against Senesco’s Factor 5A technology, the data show what we believe to be a variety of promising results regarding delivery of the technology as well as islet function and protection.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
